Overview

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
One of Disulfiram antitumor effects suggested in preclinical studies is MGMT (methyl-guanine-methyl-transferase) inhibition. Disulfiram MGMT inhibitory effect is enhanced by addition of Copper. This study evaluates the impact of DSF + Cu combination when added to standard Temozolomide in the treatment of unmethylated GBM patients.
Phase:
Phase 2
Details
Lead Sponsor:
Aurora Health Care
Treatments:
Copper
Disulfiram
Temozolomide